These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 11908560

  • 21. Antiphospholipid antibody tests: spreading the net.
    Bertolaccini ML, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GR, Khamashta MA.
    Ann Rheum Dis; 2005 Nov; 64(11):1639-43. PubMed ID: 15817655
    [Abstract] [Full Text] [Related]

  • 22. The systemic and SmD183-119-autoantigen-specific cytokine memory of Th cells in SLE patients.
    Langer S, Langnickel D, Enghard P, Undeutsch R, Burmester GR, Hiepe F, Radbruch A, Riemekasten G.
    Rheumatology (Oxford); 2007 Feb; 46(2):238-45. PubMed ID: 16880187
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Figueredo MA, Rodriguez A, Ruiz-Yagüe M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R.
    J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
    [Abstract] [Full Text] [Related]

  • 26. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK.
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS, Hayat SJ, Raghupathy R.
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [Abstract] [Full Text] [Related]

  • 32. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects.
    Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N.
    Lupus; 2012 May; 21(6):596-603. PubMed ID: 22300832
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T, Fierz W, Stoll T, Villiger PM.
    J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
    [Abstract] [Full Text] [Related]

  • 35. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.
    Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE.
    Arthritis Rheum; 2006 Dec; 54(12):3918-25. PubMed ID: 17133599
    [Abstract] [Full Text] [Related]

  • 36. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus.
    Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, Julkunen H.
    Scand J Rheumatol; 2004 Dec; 33(4):246-52. PubMed ID: 15370721
    [Abstract] [Full Text] [Related]

  • 37. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus.
    Li J, Xie H, Wen T, Liu H, Zhu W, Chen X.
    J Rheumatol; 2010 Apr; 37(4):766-75. PubMed ID: 20110525
    [Abstract] [Full Text] [Related]

  • 38. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
    Robak E, Sysa-Jedrzejowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 1997 Sep; 8(3):281-6. PubMed ID: 9346362
    [Abstract] [Full Text] [Related]

  • 39. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y.
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.